<DOC>
	<DOCNO>NCT01001234</DOCNO>
	<brief_summary>This Clinical Trial evaluate Safety Efficacy Rizatriptan Acute Treatment Migraine Children Adolescents .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Tolerability Rizatriptan Treatment Acute Migraine Children Adolescents ( MK-0462-082 AM7 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Patient weigh least 20 kg ( 44 pound ) Patient history migraine without aura &gt; 6 month &gt; = 1 &lt; = 8 moderate severe migraine attack per month 2 month prior screen Visit 1 Patient history migraine define International Headache Society ( IHS ) migraine definition Patient willing stay awake least 2 hour administration first dose study medication Patient experience satisfactory relief migraine pain nonsteroidal antiinflammatory drug ( NSAIDs ) Nacetylpaminophenol ( APAP ) treatment The parent guardian patient agree patient 's participation study indicate parental/guardian signature consent form patient assent For patient take migraine prophylactic medication , treatment regimen stable take least 3 month prior Visit 1 . Patient pregnant breastfeeding , female expect conceive within project duration study participation Patient history mild migraine attack migraine resolve less 2 hour Patient basilar hemiplegic migraine headache Patient &gt; 15 headachedays per month OR take medication acute headache 10 day per month 3 month prior screen Patient uncontrolled high blood pressure , uncontrolled diabetes , human immunodeficiency virus ( HIV ) , cancer , significant disease Patient history clinical evidence cardiovascular problem stroke Patient either demonstrate hypersensitivity experience serious adverse event response rizatriptan Patient experience satisfactory relief migraine pain prior treatment 2 adequate course 5hydroxytryptamine 1 ( 5HT1 ) agonist Patient recent history ( within past year ) current evidence drug alcohol abuse `` recreational user '' illicit drug Patient currently take monoamine oxidase inhibitor , methysergide , selective serotonin reuptake inhibitor ( SSRIs ) serotonin norepinephrine reuptake inhibitor ( SNRIs ) propranolol , unable tolerate withdrawal medication interval require Patient currently participate participate study investigational compound device within 30 day screen Patient legally mentally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>